Trientine Hydrochloride
Phase 2Small molecule
Trientine Hydrochloride is one of 66 small molecule programs targeting Proliferative Diabetic Retinopathy. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
Tanzeum
GSKPreclinical
Insulin 320
Novo NordiskPreclinical
NOVOLIN R
Novo NordiskPreclinical
Myrbetriq
AstellasPreclinical
Dostinex
PfizerPreclinical
Golytely
BayerPreclinical
Lantus
SanofiPreclinical
Trientine Hydrochloride
UUniversity of British Columbia
Phase 2
Lixisenatide
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trientine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of British Columbia